Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
The present invention provides methods for diagnosis and prognosis of lung cancer using expression analysis of one or more groups of genes, and a combination of expression analysis from a nasal epithelial cell sample. The methods of the invention provide far less invasive method with a superior detection accuracy for lung cancer when compared to any other currently available method for lung cancer diagnostic or prognosis. The invention also provides methods of diagnosis and prognosis of other lung diseases, such as lung cancer.
1. A method of processing or analyzing a biological sample of a human subject, comprising:
a) obtaining a biological sample comprising nasal epithelial cells from the nasal passage of the human subject; and
b) measuring an expression level of a plurality of genes, wherein the plurality of genes consists of AMACR, BCAP29, CPE, FLCN, PTGER4, USH1C, UBE1L, CCT4, EIF4A1, DUSP3, SDHC, CSNK1G2, TUSC4, DMTF1, MPV17, TFDP2, RREB1, ADK, FLJ11806, CDK5, RAD1, FLJ10613, CXorf34, APS, NFIC, HSF2BP, AOC2, FLJ14107, USP34, KIAA0894, MPP2, ATP6V1E1, DNAJB6, NCOA3, KPNA4, COQ7, BTN3A1, ATM, HFE, ATRN, ATP8A1, ELOVL5, IVL, N2N, THEA, PRDX2, AKAP11, NKX3-1, PRPS1 and GPC6.
2. The method of claim 1 , wherein the expression levels of gene transcripts are measured by reverse-transcription polymerase chain reaction (RT-PCR) analysis, nucleic acid chip analysis, or messenger RNA analysis.
3. The method of claim 1 , wherein the human subject is a smoker or former smoker.
4. The method of claim 1 , wherein the human subject has been exposed to an airway pollutant.
5. The method of claim 4 , wherein the airway pollutant is cigarette or cigar smoke.
6. The method of claim 4 , wherein the airway pollutant is smog or asbestos.
7. The method of claim 1 , wherein the human subject is suspected of having eosinophilic pneumonia, hypersensitivity pneumonitis, pulmonary alveolar proteinosis, systemic sclerosis, idiopathic pulmonary hemosiderosis, or pulmonary fibrosis.
8. The method of claim 1 , further comprising obtaining an additional biological sample from the human subject.
9. The method of claim 8 , wherein the additional biological sample is obtained from the subject at least one week after obtaining the biological sample.
10. The method of claim 1 , further comprising confirming an integrity of ribonucleic acids of the biological sample.
11. The method of claim 1 , wherein the human subject is asymptomatic for a lung cancer.
12. The method of claim 1 , wherein the human subject has not been previously diagnosed with a lung cancer.